



Subt. Form PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYZ-069CN
(47508.556)Application Number
09/896,692Applicant
AgrawalFiling Date
June 29, 2001

Group Art Unit

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J3	4,309,404	01/05/82	DeNeale et al.	424	32	
	4,309,406	01/05/82	Guley et al.	424	32	
	4,556,552	12/03/85	Porter et al.	424	32	
	4,704,295	11/03/87	Porter et al.	427	3	
	5,627,277	01/07/94	Cohen et al.	536	25.4	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
J3	WO 94/08004	04/14/94	PCT	C12N	15/11		
	WO 95/11813	07/13/95	PCT	C07H	1/06		
	WO 97/06662A	02/27/97	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
J3	A1	Milner et al. (1977) "Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays," <i>Nature Biotech.</i> 15:537-541
	A2	Wickstrom (1986) "Oligodeoxynucleotide Stability in Subcellular Extracts and Culture Media," <i>J. Biochem. Biophys. Meth.</i> 13:97-102
	A3	Zamecnik et al. (1986) "Inhibition of Replication and Expression of Human T-cell Lymphotropic Virus Type III in Cultured Cells by Exogenous Synthetic Oligonucleotides Complementary to Viral RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:4143-4147
	A4	Agrawal et al. (1987) "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation," <i>Tetrahedron. Lett.</i> 28 (31):3539-3542
	A5	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoroamidates and Phosphorothioates As Inhibitors of Human Immunodeficiency Virus," <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
	A6	Goodchild et al. (1988) "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 85:5507-5511
	A7	Matsukura et al. (1988) "Synthesis of Phosphorothioate Analogues of Oligodeoxyribonucleotides and Their Antiviral Activity Against Human Immunodeficiency Virus (HIV)," <i>Gene</i> 72:343-347
	A8	Sarin et al. (1988) "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85:7448-7451
	A9	Agrawal et al. (1989) "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and Their Phosphorothioate Analogues," <i>Proc. Natl. Acad. Sci. USA</i> 86:7790-7794
	A10	Matsukura et al. (1989) "Regulation of Viral Expression of Human Immunodeficiency Virus <i>In Vitro</i> by an Antisense Phosphorothioate Oligodeoxynucleotide Against <i>rev(art/trs)</i> In Chronically Infected Cells," <i>Proc. Natl. Acad. Sci. USA</i> 86:4244-4248
	A11	Gennaro (ed.) (1990) <i>Remington's Pharmaceutical Sciences</i> (18 th Ed.) Mack Publishing Co., Easton, PA
	A12	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90:543-583
	A13	Agrawal (1991) in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> , (Wickstrom, ed.) Wiley-Liss, Inc., pp. 143-158
	A14	Harrison et al. (1991) in <i>RNA Tumor Viruses</i> (Coffin et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 235

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. Form PTO-1449

Docket Number
HYZ-069CN
(47508.556)Application Number
09/896,692O I P INFORMATION DISCLOSURE
IN AN APPLICATION

SEP 07 2001

(Use several sheets if necessary)

Applicant
AgrawalFiling Date
June 29, 2001

Group Art Unit

2

OF

2

- 73
- | | |
|-----|--|
| A15 | Vickers et al. (1991) "Inhibition of HIV-LTR Gene Expression by Oligonucleotides Targeted to the TAR Element," <i>Nucleic Acids Res.</i> 19:3359-3368 |
| A16 | Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," <i>Trends in Biotechnology</i> 10:152-158 |
| A17 | Agrawal et al. (1992) "Cellular Uptake and Anti-HIV Activity in Oligonucleotides and Their Analogs," <i>Gene Regulation: Biology of Antisense RNA and DNA</i> (Erickson and Izant, eds.) Raven Press Ltr., New York, pp. 273-283 |
| A18 | Matsukura et al. (1992) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application," <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> , Wiley-Liss, Inc., pp. 159-178 |
| A19 | Tang et al. (1993) "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity," <i>Nucleic Acids Res.</i> 20:2729-2735 |
| A20 | Brown (1994) "A Brief History of Oligonucleotide Synthesis. Protocols for Oligonucleotides and Analogs," <i>Methods in Molecular Biology</i> 20: 1-8 |
| A21 | Freehler (1994) "Oligodeoxynucleotide Synthesis," <i>Methods in Molecular Biology</i> 20:63-80 |
| A22 | Sonveaux (1994) "Protecting Groups in Oligonucleotide Synthesis," <i>Methods in Molecular Biology</i> 26:1-72 |
| A23 | Agrawal et al. (1995) "Tissue Distribution and <i>In Vivo</i> Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration," <i>Biochem. Pharmacol.</i> 50(4):571-576 |
| A24 | Iyer et al. (1995) "A Novel Nucleoside Phosphoroamidite Synthon Derived From 1 <i>R</i> , 2 <i>S</i> -Ephedrine," <i>Tetrahedron Asymmetry</i> 6:1051-1054 |
| A25 | Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 374:546-549 |
| A26 | Gewirtz et al. (1996) "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise," <i>Proc. Natl. Acad. Sci. USA</i> 93:3161-3163 |
| A27 | Rojanasakul (1996) "Antisense Oligonucleotide Therapeutics," <i>Adv. Drug Del. Rev.</i> Vol. 18:115-131 |
| A28 | Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," <i>Biochem. Pharmacol.</i> 51(2):173-182 |
| A29 | Zhang et al. (1996) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration," <i>J. Pharmacol. Expt. Thera.</i> 278:1-5 |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.